Cellular pharmacology of the combination of oxaliplatin with topotecan in the IGROV-1 human ovarian cancer cell line.

The clinical development of combinations of clsplatin or carboplatin with DNA topoisomerase I (Topo I) inhibitors is based on their overlapping spectrum of antitumor activity and their In vitro synergy, but is limited by significant hematotoxicity. We studied the cellular Interactions between oxalip